Yahoo · Sep 24, 2026
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Chief executive Warner Biddle said the therapy’s durability “exceeded even our expectations.”
KY
NASDAQ · KYTX
Kyverna Therapeutics, Inc.
Healthcare · Biotechnology
$6.32
Down-$0.16 (-2.53%)
Updated Oct 7, 2026, 12:00 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 364.57M
- P/E ratio
- -2.27
- Dividend yield
- 0.00%
- 52-week range
- $6.00 – $11.62
- Volume
- 813.48K
- Avg. volume
- 697.76K
Price performance · KYTX
KYTX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
KYTX closed at $6.32 after 20 trading sessions, down 21.69% for the selected period.
- Last close
- $6.32
- Period change
- -21.69%
- Period low
- $6.22
- Period high
- $8.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $6.30 | $6.435 | $6.00 | $6.32 | 813.48K |
| Oct 2, 2026 | $6.62 | $6.7537 | $6.17 | $6.22 | 1.18M |
| Oct 1, 2026 | $6.80 | $6.91 | $6.51 | $6.52 | 788.5K |
| Sep 30, 2026 | $6.875 | $7.10 | $6.73 | $6.80 | 746.99K |
| Sep 29, 2026 | $6.83 | $6.95 | $6.75 | $6.84 | 827.67K |
| Sep 28, 2026 | $6.72 | $6.95 | $6.65 | $6.82 | 997.82K |
| Sep 25, 2026 | $6.99 | $7.015 | $6.6201 | $6.81 | 1.5M |
| Sep 24, 2026 | $7.80 | $7.92 | $6.675 | $6.99 | 3.28M |
| Sep 23, 2026 | $7.50 | $7.54 | $6.99 | $7.07 | 1.03M |
| Sep 22, 2026 | $7.18 | $7.59 | $7.11 | $7.51 | 836.8K |
| Sep 21, 2026 | $7.25 | $7.26 | $6.99 | $7.12 | 678.46K |
| Sep 18, 2026 | $7.02 | $7.19 | $7.00 | $7.13 | 961.26K |
| Sep 17, 2026 | $7.11 | $7.18 | $6.96 | $7.04 | 530.95K |
| Sep 16, 2026 | $7.02 | $7.155 | $6.855 | $6.90 | 685.75K |
| Sep 15, 2026 | $7.34 | $7.34 | $6.87 | $6.96 | 1.07M |
| Sep 14, 2026 | $7.25 | $7.49 | $7.21 | $7.40 | 533.91K |
| Sep 11, 2026 | $7.47 | $7.59 | $7.205 | $7.26 | 751.63K |
| Sep 10, 2026 | $7.51 | $7.53 | $7.34 | $7.35 | 854.46K |
| Sep 9, 2026 | $8.00 | $8.165 | $7.595 | $7.64 | 918.29K |
| Sep 8, 2026 | $8.17 | $8.21 | $7.97 | $8.07 | 586.39K |
Latest KYTX news
The latest Smart Investors Daily articles mentioning KYTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
KYTX research
Overview
Company profile and research snapshot.
Company profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | JP Morgan | Overweight | — |
| Apr 23, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 24, 2026
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow
2026-09-24. The following slide deck was published by Kyverna Therapeutics, Inc.
Yahoo · Sep 24, 2026
Kyverna stock jumps on positive one-year therapy data
Investing.com -- Kyverna Therapeutics Inc (NASDAQ:KYTX) shares rose nearly 10% in early trade Thursday following the release of positive one-year durability data for its miv-cel therapy in stiff person syndrome and generalized myasthenia gravis.
SeekingAlpha · Sep 24, 2026
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials September 24, 2026 8:00 AM EDTCompany...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
